Agmatine Sulfate Capsules

Product Description

Agmatine is a decarboxylated derivative of the amino acid L-arginine (1). L-arginine is an amino acid which may improve exercise duration (2). Our Agmatine Sulfate capsules support cognition.

Agmatine Sulfate Benefits

Agmatine Sulfate is emerging as a subject of interest in the medical community, but thus far, there has not been a large amount of research or trials conducted with humans.*

The following are examples of dynamics associated with Agmatine Sulfate through the animal model and may not be representative of the effects in the human body:

• Supports mitochondrial health (in vitro)(ref)*
• Promotes antioxidant activity (in vitro)(ref)*
• May provide mood support (ref)(ref)*

Agmatine Sulfate Mode of Action

Agmatine is an amine molecule that is involved in signaling in the human body.  It is a bacterial byproduct and is distinguished by the enzyme which synthesizes agmatine from arginine and can be found in fermented foods such as wine, beer, sake, fish, meat products, and coffee. (1).

Agmatine is endogenously produced and is found in the spinal cord and brain and works both as an N-methyl-D-aspartate (NMDAR) antagonist and a nitric oxide synthase (NOS) inhibitor (3).  Research at this time proposes that agmatine is a neurotransmitter-neuromodulator, as it is made, stored, and released in the brain.  It is also found in neurons and neural axon terminals.  Agmatine interacts with cell-specific receptors and interacts with actions within the central nervous system.  However, its role in brain function has not yet been determined because researchers are still studying its biosynthesis and degradation (4).

Agmatine is expressed in the brain in high concentrations in the inferior section of the hippocampus and cerebral cortex.  It crosses the blood-brain barrier.  It is interesting to note that administering L-arginine does not increase agmatine concentrations itself (1).

Agmatine promotes antioxidant activity by preventing the oxidation of sulfhydryl groups and decreases hydrogen peroxide content (5).

Agmatine Sulfate Dosage

Pure Nootropics’ Agmatine Sulfate provides 500 mg per 1 capsule.  Suggested use for adults is 1 capsule by mouth daily, or as directed by your healthcare practitioner.

Agmatine Sulfate Side Effects and Toxicity

Side effects noted in the human clinical study include transient gastrointestinal discomfort at high doses (1).

A lethal dose was achieved in mice at a dose of 300 mg/kg, 3200 mg/kg in rabbits, and 980 mg/kg in rats (1).

There is limited data on toxicity in humans, but studies have reported no known side-effects.  Short term safety data is available that shows it is safe for up to 21 days.  Another study tested the long-term effects of administration up to 115 days and found no adverse effects (6).

For further information, please see our References Tab above.

AGMATINE SULFATE CERTIFICATE OF ANALYSIS 03/2018

The references below are not meant to imply that any of our products treat, cure, or diagnose any disease or human condition. References to clinical studies and pre-clinical studies may use varying dosages and may not represent the dosages or subsequent results of products we sell; however, the references provided are pertinent to the subject supplement itself. References provided are intended for research and informational purposes only and do not represent the entire body of knowledge available on the subject(s) referenced; nor do they represent all possible outcomes associated with the subject(s) referenced including, but not limited to, adverse effects, precautions, or chemical interactions within the human body. The Content provided on this website is not intended to be a replacement for professional medical advice, treatment or diagnosis. Never ignore the advice of a medical professional or delay in attaining professional advice because of information or impressions you gather on this website. Choosing to rely on any information provided by the Content of this website is solely at your own risk. We encourage our audience to do their own research beyond the resources we have provided so your decision is as educated as possible.

The following are examples of dynamics associated with Agmatine Sulfate through the animal model and may not be representative of the effects in the human body:
• Supports mitochondrial health (in vitro)*
• Promotes antioxidant activity (in vitro) *

Arndt, Mary Ann et al. “The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis.” American journal of physiology. Cell physiology vol. 296,6 (2009): C1411-9. doi:10.1152/ajpcell.00529.2008
• May provide mood support (in rodents)*
Aricoglu, Feyza. “Is Agmatine an Endogenous Anxiolytic/Antidepressant Agent?” Annals of the New York Academy of Sciences, 24 Jan. 2006, doi: https://doi.org/10.1196/annals.1304.014.
Freitas, AE, et al. “Agmatine, a Potential Novel Therapeutic Strategy for Depression.” Eur Neuropsychopharmacol, vol. 26, no. 12, Dec. 2016, pp. 1885–1889., doi:10.1016/j.euroneuro.2016.10.013. Epub .

1. “Agmatine.” Examine.com, published Oct 26, 2014. Last updated Oct 1, 2014. https://examine.com/supplements/agmatine/.
2. “Arginine.” Examine.com, published Oct 16, 2014. Last updated Jun 14, 2018. https://examine.com/supplements/arginine/.
3. Fairbanks, C A et al. “Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury.” Proceedings of the National Academy of Sciences of the United States of America vol. 97,19 (2000): 10584-9.
4. Reis, DJ, and S Regunathan. “Agmatine: a Novel Neurotransmitter?” Adv. Pharmacol, vol. 42, 1998, pp. 645–9., www.ncbi.nlm.nih.gov/pubmed/9327985.
5. Arndt, Mary Ann et al. “The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis.” American journal of physiology. Cell physiology vol. 296,6 (2009): C1411-9. doi:10.1152/ajpcell.00529.2008
6. Gilad, GM, and VH Gilad. “Evidence for Oral Agmatine Sulfate Safety–a 95-Day High Dosage Pilot Study with Rats.” Food Chem Toxicol., vol. 62, Dec. 2013, pp. 758–62., doi:10.1016/j.fct.2013.10.005.